Published in Proc Natl Acad Sci U S A on May 09, 1995
Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol (2009) 1.07
Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol (1997) 0.99
Detection of endothelial nitric oxide synthase and NADPH-diaphorase in experimentally induced hyperoxaluric animals. Urol Res (2005) 0.75
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem (1982) 27.26
Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A (1993) 13.27
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol (1987) 6.93
Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res (1988) 5.09
Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J Immunol (1987) 5.00
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J Cell Biol (1989) 3.55
Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med (1993) 2.98
The progression of renal disease. N Engl J Med (1988) 2.70
Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest (1990) 2.56
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A (1993) 2.46
In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A (1993) 2.40
Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery (1992) 2.26
Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med (1991) 2.08
Temporal expression of different pathways of 1-arginine metabolism in healing wounds. J Immunol (1990) 2.06
Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest (1993) 1.97
Arginine metabolism in wounds. Am J Physiol (1988) 1.81
Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest (1995) 1.79
Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int (1987) 1.78
L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest (1991) 1.73
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med (1990) 1.62
Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett (1988) 1.61
Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery (1990) 1.56
Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc Natl Acad Sci U S A (1993) 1.54
Arginine: biochemistry, physiology, and therapeutic implications. JPEN J Parenter Enteral Nutr (1986) 1.48
Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis (1992) 1.47
One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest (1993) 1.42
Role of L-arginine-nitric oxide pathway in myocardial reoxygenation injury. Am J Physiol (1992) 1.41
Protein oxidation associated with aging is reduced by dietary restriction of protein or calories. Proc Natl Acad Sci U S A (1992) 1.36
Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating rate of cultured cardiac myocytes. Mol Endocrinol (1992) 1.35
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int (1992) 1.32
Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest (1993) 1.18
Arginine: an essential amino acid for injured rats. Surgery (1978) 1.14
Glomeruli synthesize nitrite in experimental nephrotoxic nephritis. Kidney Int (1990) 1.11
Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest (1993) 1.05
Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A (1991) 0.96
Glomeruli synthesize nitrite in active Heymann nephritis; the source is infiltrating macrophages. Kidney Int (1991) 0.96
Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol (1994) 0.87
Regulation of ornithine metabolism. Enzyme (1981) 0.85
Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest (1993) 0.84
EDRF role in renal function and blood pressure of normal rats and rats with obstructive uropathy. Kidney Int (1992) 0.82
Transforming growth factor-beta improves healing of radiation-impaired wounds. J Invest Dermatol (1991) 0.82
Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int (1992) 0.79
The effects of an arginine-free enteral diet on wound healing and immune function in the postsurgical rat. J Pediatr Surg (1991) 0.78
L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int (1994) 0.76
Integrin signaling. Science (1999) 16.44
Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature (1984) 14.25
Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer (1977) 11.99
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell (1985) 8.55
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 8.11
Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 7.89
Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol (1996) 5.62
Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors. Science (1986) 5.58
Integrins and anoikis. Curr Opin Cell Biol (1997) 5.38
Organ targeting in vivo using phage display peptide libraries. Nature (1996) 5.20
Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell (1990) 5.15
Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc Natl Acad Sci U S A (1984) 5.13
Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 4.90
Fibronectin: current concepts of its structure and functions. Coll Relat Res (1981) 4.82
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Fibronectin: purification, immunochemical properties, and biological activities. Methods Enzymol (1982) 4.45
A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci U S A (1985) 4.44
Amino acid sequence of the human fibronectin receptor. J Cell Biol (1987) 4.08
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96
Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J (1994) 3.92
Interaction of soluble fibroblast surface antigen with fribrinogen and fibrin. J Exp Med (1975) 3.91
Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol (1997) 3.89
Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med (1999) 3.72
Location of the cell-attachment site in fibronectin with monoclonal antibodies and proteolytic fragments of the molecule. Cell (1981) 3.64
Affinity of fibronectin to collagens of different genetic types and to fibrinogen. J Exp Med (1978) 3.46
Disappearance of a major cell-type specific surface glycoprotein antigen (SF) after transformation of fibroblasts by Rous sarcoma virus. Int J Cancer (1974) 3.24
Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res (2000) 3.24
Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci U S A (1983) 3.23
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 3.16
Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc Natl Acad Sci U S A (1986) 3.16
The human laminin receptor is a member of the integrin family of cell adhesion receptors. Science (1988) 3.03
Synthetic peptide with cell attachment activity of fibronectin. Proc Natl Acad Sci U S A (1983) 2.97
Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases. Mol Cell Biol (1996) 2.94
The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci U S A (1995) 2.90
Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther (2014) 2.88
Multiple domains of the large fibroblast proteoglycan, versican. EMBO J (1989) 2.86
Distribution of fibroblast surface antigen in the developing chick embryo. J Exp Med (1975) 2.85
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int (2006) 2.85
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest (1994) 2.81
Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 2.79
Regulation of the fibronectin receptor affinity by divalent cations. J Biol Chem (1988) 2.78
Fibroblast surface antigen: a new serum protein. Biochim Biophys Acta (1973) 2.71
Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J (1985) 2.69
Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol (1981) 2.65
Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest (1998) 2.65
The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci U S A (1985) 2.64
Distribution of fibroblast surface antigen: association with fibrillar structures of normal cells and loss upon viral transformation. J Exp Med (1974) 2.62
Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem (1987) 2.62
Basement membrane glycoprotein laminin binds to heparin. FEBS Lett (1980) 2.60
A novel fibronectin receptor with an unexpected subunit composition (alpha v beta 1). J Biol Chem (1990) 2.58
Laminin promotes neuritic regeneration from cultured peripheral and central neurons. J Cell Biol (1983) 2.58
cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc Natl Acad Sci U S A (1986) 2.58
Association of insulin receptor substrate-1 with integrins. Science (1994) 2.56
Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest (1990) 2.56
Integrin activation by R-ras. Cell (1996) 2.50
Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) (1995) 2.45
Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int (2007) 2.42
Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J (1997) 2.40
Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science (1996) 2.38
Superfibronectin is a functionally distinct form of fibronectin. Nature (1994) 2.38
Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J Biol Chem (1993) 2.37
Novel human serum protein from fibroblast plasma membrane. Nature (1974) 2.35
Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol (1999) 2.34
Endothelial cells use alpha 2 beta 1 integrin as a laminin receptor. J Cell Biol (1989) 2.31
Amino acid sequence of the vitronectin receptor alpha subunit and comparative expression of adhesion receptor mRNAs. J Biol Chem (1987) 2.29
Mapping of domains in human laminin using monoclonal antibodies: localization of the neurite-promoting site. J Cell Biol (1986) 2.29
Activation of protein kinase C precedes alpha 5 beta 1 integrin-mediated cell spreading on fibronectin. J Biol Chem (1993) 2.27
Cell surface distribution of fibronectin and vitronectin receptors depends on substrate composition and extracellular matrix accumulation. J Cell Biol (1988) 2.26
Alpha-fetoprotein: immunochemical purification and chemical properties. Expression in normal state and in malignant and non-malignant liver disease. Transplant Rev (1974) 2.26
Detachment of cells from culture substrate by soluble fibronectin peptides. J Cell Biol (1985) 2.26
Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol (1987) 2.25
Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. Cancer Res (1981) 2.21
Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis. N Engl J Med (1974) 2.20
Nehprotic syndrome with glomerular mesangial IgM deposits. Lab Invest (1978) 2.19
Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A (1992) 2.18
Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J Biol Chem (1995) 2.17
alpha-Fetoprotein in cancer and fetal development. Adv Cancer Res (1979) 2.16
Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest (1982) 2.12
Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry (1999) 2.10
Molecular cloning and sequence analysis of a chondroitin sulfate proteoglycan cDNA. Proc Natl Acad Sci U S A (1985) 2.08
The alpha v beta 1 integrin functions as a fibronectin receptor but does not support fibronectin matrix assembly and cell migration on fibronectin. J Cell Biol (1993) 2.06
A cell surface receptor complex for collagen type I recognizes the Arg-Gly-Asp sequence. J Cell Biol (1987) 2.04
Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int (1990) 2.04
Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J Cell Biol (1979) 2.04
The cell attachment domain of fibronectin. Determination of the primary structure. J Biol Chem (1982) 2.03
Distribution and isolation of four laminin variants; tissue restricted distribution of heterotrimers assembled from five different subunits. Cell Regul (1990) 2.02
TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int (1997) 2.01
Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins. Proc Natl Acad Sci U S A (1987) 2.00
Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. J Biol Chem (1989) 2.00
Studies of carcino-fetal proteins. 3. Development of a radioimmunoassay for -fetoprotein. Demonstration of -fetoprotein in serum of healthy human adults. Int J Cancer (1971) 1.97
A fibronectin self-assembly site involved in fibronectin matrix assembly: reconstruction in a synthetic peptide. J Cell Biol (1992) 1.94
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med (1996) 1.93